Vanda's Tradipitant Improves Itch and Disease Severity in AD Patients

Wednesday, September 13, 2017 | Atopic Dermatitis , Product Launches and Updates , Research and Publications


Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity,  according to results from an eight-week randomized Phase 2 clinical.

Tradipitant is an oral neurokinin-1 receptor (NK-1R) antagonist licensed by Vanda from Eli Lilly and Company (Lilly) in April 2012. Vanda expects to meet with the US Food and Drug Administration  in the near future to further define and confirm the clinical development path towards registration of tradipitant in the treatment of AD patients.

In the study, tradipitant demonstrated significant and clinically meaningful improvement in a number of measures of itch.  Specifically, significant improvements were observed in the measurement of Worst Itch Visual Analog Scale (VAS) (p=0.019). Tradipitant also showed significant effects in a responder analysis for Worst Itch in patients who achieved improvements of greater than or equal to 40 points improvement from baseline in Worst Itch VAS scores (p=0.037) or greater than or equal to 30 points (p=0.049). On the pre-specified primary endpoint of Average Itch VAS, tradipitant showed improvement over placebo, but this improvement was not significant due to high placebo effect and the lack of sensitivity of this measure.

Consistent with the observed improvements in Worst Itch, which is associated with scratching behavior, tradipitant also demonstrated disease-modifying properties by showing significant improvement in the Total SCORAD scale (p=0.008) and Objective SCORAD scale (p=0.005). Specifically, tradipitant showed significant improvements in several clinical features of AD severity including excoriation, erythema, oozing and dryness.

These clinically meaningful effects were also accompanied by significant improvements in the Clinical Global Impression scale - Change (CGI-C) (p=0.007), the Patient Global Impression scale (PGI-C) Itch (p=0.024) the PGI-C AD (p=0.007). Similarly, tradipitant also showed direct patient reported benefits as measured by the Patient Benefit Index scale (PBI) (p=0.037). 

"It's exciting to see results here with significant and highly meaningful improvements in both worst itch as well as a recovery in the lesions for patients in the study," says Gil Yosipovitch, MD, Professor of Dermatology, Miller School of Medicine, and Director of the Miami Itch Center at the University of Miami as well as an investigator in this study, in a news release. "These results over 8 weeks provide further confirmation that breaking the itch-scratch cycle causing neural sensitization can have a profound benefit for patients and help ameliorate  AD itself. Today, there are limited treatment options for the many patients who suffer from atopic dermatitis, making this study outcome a very promising step towards becoming a major advancement in the armamentarium for physicians."

In this Phase II study, 168 patients were randomized 1:1 to receive either tradipitant 85 mg BID or placebo for a period of 8 weeks. Entry criteria included patients suffering from moderate or severe itching with mild to severe atopic dermatitis excluding only the most severe patients with an upper limit of 80 on total SCORAD (average baseline total SCORAD=47). Tradipitant was found to be safe and well tolerated with minimal adverse events recorded.

If these results are further confirmed in future studies, tradipitant may become a first line pharmacological option in the treatment of patients with AD in need of systemic treatment, the company states.

The detailed results of this study are slated to be presented in upcoming meetings and prepared for peer-reviewed publications.

 

 

Next Story

Comments

You must be logged in to leave a comment.